Dent disease is a rare genetic kidney disorder that impairs the kidneys’ ability to reabsorb proteins and calcium. It primarily affects males, typically showing up in childhood or adolescence, and progresses to kidney failure in 30% to 80% of affected men between the ages of 30 and 50. The condition is caused by mutations on the X chromosome, which is why it hits males hardest while female carriers usually experience only mild symptoms, if any.
How Dent Disease Affects the Kidneys
Your kidneys filter blood constantly, and most of the useful substances that pass through the filter, including small proteins, get recaptured by cells lining the proximal tubule (the first stretch of tubing after the filter). In Dent disease, a key transporter inside those cells doesn’t work properly. This transporter normally helps acidify tiny internal compartments called endosomes, which is a critical step for releasing captured proteins so the cell can grab more. Without that acidification step, the recycling process stalls. Proteins that should be reclaimed slip through and end up in the urine instead.
The same tubule dysfunction disrupts calcium handling. Excess calcium spills into the urine, a condition called hypercalciuria, which occurs in roughly 95% of affected males. Over time, that calcium can crystallize inside the kidney tissue (nephrocalcinosis, seen in about 75% of cases) or form kidney stones (in about 50%). This combination of protein loss, calcium buildup, and stone formation gradually damages kidney tissue and drives the disease toward kidney failure.
Type 1 vs. Type 2
Dent disease comes in two forms, distinguished by which gene is mutated. Type 1 accounts for the majority of cases and involves mutations in a gene called CLCN5, which codes for the chloride transporter described above. More than 200 different CLCN5 mutations have been identified so far, meaning the genetic picture varies widely from family to family. Type 1 has been reported in roughly 250 families worldwide.
Type 2 is much rarer, reported in only about 25 individuals. It results from mutations in the OCRL gene, which is also responsible for a more severe condition called Lowe syndrome. People with Dent disease type 2 may have features that overlap with Lowe syndrome, including cataracts, mild intellectual disability, and elevated muscle enzymes, though the kidney problems remain the central issue. About 10% to 15% of all Dent disease patients carry OCRL mutations.
Signs and Symptoms
The hallmark of Dent disease is low-molecular-weight proteinuria, meaning small proteins that the kidneys should recapture are instead lost in the urine. This is present in virtually all affected males and is often the first abnormality detected, sometimes on a routine urine test in childhood. On its own, this type of protein loss doesn’t cause obvious symptoms, so it can go unnoticed for years.
More noticeable problems tend to develop over time. Kidney stones can cause flank pain and blood in the urine. Nephrocalcinosis may be picked up on imaging done for another reason. Some children develop rickets or bone pain because the kidneys also lose phosphate, which weakens bones. There is considerable variability even within the same family: one brother may form stones in his teens while another doesn’t develop them until his thirties, or at all.
Female carriers of the mutation occasionally show mild proteinuria or elevated urinary calcium, and rarely develop kidney stones. Full-blown disease in women is uncommon because their second X chromosome typically compensates for the faulty one.
How It’s Diagnosed
Diagnosis requires three findings together: low-molecular-weight proteinuria, hypercalciuria, and at least one additional feature such as nephrocalcinosis, kidney stones, blood in the urine, low blood phosphate, or declining kidney function. Because these features overlap with other kidney conditions, Dent disease is frequently misdiagnosed or missed entirely, which makes it hard to pin down how common it truly is.
Genetic testing confirms the diagnosis by identifying a mutation in CLCN5 or OCRL. This step also determines whether the disease is type 1 or type 2, which matters because type 2 warrants screening for the extra-renal features like cataracts and developmental concerns.
Disease Progression and Outlook
Dent disease is progressive but moves at different speeds in different people. Kidney function may remain stable for years before declining. The broad estimate is that 30% to 80% of affected males reach end-stage kidney failure between ages 30 and 50, though some don’t reach that point until their sixties or later. The wide range reflects genuine unpredictability: even brothers with the same mutation can follow different trajectories.
Once kidney failure develops, the options are dialysis or transplantation. A transplanted kidney does not carry the genetic defect, so Dent disease does not recur in the new organ.
Management and Treatment
There is no cure for Dent disease. Treatment focuses on slowing kidney damage and managing complications. Reducing urinary calcium is a primary goal because it’s the calcium that drives stone formation and nephrocalcinosis. Thiazide diuretics, a class of medication that lowers urinary calcium output, are sometimes used, though they must be monitored carefully because they can lower potassium and blood volume. Citrate supplements may help prevent stones by binding calcium in the urine.
Dietary modifications play a supporting role. Keeping salt intake low helps reduce calcium excretion, since the kidney handles sodium and calcium through overlapping pathways. Adequate hydration dilutes urinary calcium and makes stones less likely to form. If phosphate wasting is significant enough to cause bone disease, phosphate and vitamin D supplements can help protect bone health.
Regular monitoring of kidney function, urinary calcium, and imaging for stones or calcification helps clinicians adjust the plan as the disease evolves. A set of clinical practice recommendations published in Nephrology Dialysis Transplantation, developed through expert consensus and a systematic literature review, now provides standardized guidance for diagnosis and long-term management of the condition.